 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12...891011121314151617181920» |
- || semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical, Journal: GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. (Pubmed Central) - Nov 12, 2020
With some patients having a preference for oral medications, the development of an oral GLP-1RA is a logical approach to improving treatment options for patients with T2D. Co-formulation of semaglutide with an absorption enhancer has enabled the development and recent approval of the first oral GLP-1RA, oral semaglutide, which has the potential to expand use of GLP-1RAs in clinical practice.
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: PIONEER TEENS: A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (clinicaltrials.gov) - Nov 9, 2020
P3, N=132, Recruiting, Sponsor: Novo Nordisk A/S
Co-formulation of semaglutide with an absorption enhancer has enabled the development and recent approval of the first oral GLP-1RA, oral semaglutide, which has the potential to expand use of GLP-1RAs in clinical practice. Not yet recruiting --> Recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide-1 Receptor Agonist. (Pubmed Central) - Nov 7, 2020
The oral formulation of semaglutide was studied in the PIONEER trials, demonstrating similar efficacy to the currently available GLP-1 RAs in regards to HbA1c lowering and weight loss. Although PIONEER 6 trial suggests positive effects on cardiovascular mortality with oral semaglutide, these benefits may not fully be appreciated until the completion of the SOUL trial.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Good morning! $NOVO pays $1.8bn to take out Emisphere, its oral semaglutide partner (Twitter) - Nov 6, 2020
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial initiation date: Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder (clinicaltrials.gov) - Nov 3, 2020
P2, N=60, Not yet recruiting, Sponsor: University Health Network, Toronto
Although PIONEER 6 trial suggests positive effects on cardiovascular mortality with oral semaglutide, these benefits may not fully be appreciated until the completion of the SOUL trial. Initiation date: Sep 2020 --> Jan 2021
- | Rybelsus (semaglutide oral) / Novo Nordisk
Novo's Rybelsus launch is on the up-and-up after taking pandemic hit: execs @FiercePharma https://t.co/BwJ5gEJrxT (Twitter) - Nov 3, 2020
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice (clinicaltrials.gov) - Oct 29, 2020
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Initiation date: Sep 2020 --> Jan 2021 Not yet recruiting --> Enrolling by invitation
- | Byetta (exenatide) / AstraZeneca, semaglutide SC once-daily (NN9536) / Novo Nordisk
Retrospective data, Journal: Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis. (Pubmed Central) - Oct 28, 2020
The indirect comparison and ranking probability results have shown that one weekly semaglutide and oral semaglutide seems to be the preferred option in patients with T2DM and established or at high risk of CVD. This result can aid health care providers, pharmacy and therapeutics committees in hospitals, and insurance companies when deciding which GLP1RA to start or add to their formulary.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets (clinicaltrials.gov) - Oct 26, 2020
P1, N=274, Active, not recruiting, Sponsor: Novo Nordisk A/S
This result can aid health care providers, pharmacy and therapeutics committees in hospitals, and insurance companies when deciding which GLP1RA to start or add to their formulary. Recruiting --> Active, not recruiting
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (clinicaltrials.gov) - Oct 25, 2020
P, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice (clinicaltrials.gov) - Oct 25, 2020
P, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: Den Galenus-Preis 2020 in der Kategorie #PrimaryCare gewinnt @novonordisk für Rybelsus®, die erste und bislang einzige oral verfügbare Formulierung eines GLP-1-Analogons. Herzlichen Glückwunsch! Mehr Infos: https://t.co/YHJ1CZP9Jg #Galenus20 (Twitter) - Oct 22, 2020
- |||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: PIONEER TEENS: A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (clinicaltrials.gov) - Oct 22, 2020
P3, N=132, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6 (Simulive) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3629;
Semaglutide was associated with a significantly smaller decline in kidney function than PBO in subjects with T2D at high CV risk across tested BL eGFR categories; the data suggest the main benefit might be observed in those with kidney disease. Funding: Commercial Support
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1805;
Semaglutide (subcutaneous and oral) is an effective glucose-lowering agent in subjects with T2D, independently of baseline eGFR, including in those with chronic kidney disease. Funding: Commercial Support
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Novo Nordisk debuts animated Rybelsus ad after COVID-19 nixed film shoot https://t.co/0UT17GYArw (Twitter) - Oct 6, 2020
- [VIRTUAL] EFFECTS OF SEMAGLUTIDE VS COMPARATORS ON CARDIOVASCULAR EVENTS ACROSS A CONTINUUM OF BASELINE CARDIOVASCULAR RISK: COMBINED ANALYSIS OF THE SUSTAIN AND PIONEER TRIALS (Inxpo Platform, Simulive + Text Q&A) - Oct 4, 2020 - Abstract #CCCCanada2020CCC_Canada_90;
Fewer major adverse cardiovascular events (MACE) were observed with semaglutide vs placebo in cardiovascular outcomes trials (CVOTs) in subjects with type 2 diabetes (T2D) at high risk of cardiovascular (CV) events (once-weekly subcutaneous semaglutide in SUSTAIN 6; once-daily oral semaglutide in PIONEER 6). To better understand the CV effect of semaglutide in a broader range of subjects with T2D, including those at lower CV risk, we conducted a post hoc analysis of semaglutide and comparator (placebo, sitagliptin, exenatide extended release, insulin glargine, dulaglutide, liraglutide, and empagliflozin) data from all phase 3a SUSTAIN and PIONEER trials across the continuum of baseline CV risk characterizing a broad T2D population.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] The Cost-Effectiveness of ORAL Semaglutide in Patients Treated with Currently Available GLP-1 Receptor Agonists - a UK Perspective () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_66;
The comparison provided here is relevant to payers, as it demonstrates what they are currently paying versus the new oral formulation. Physician and patient preference is important when selecting which GLP-1RA to prescribe for a patient.
- | Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Journal: Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. (Pubmed Central) - Oct 3, 2020
P3
Semaglutide reduced the risk of MACE vs comparators across the continuum of baseline CV risk in a broad T2D population. Trial registrations ClinicalTrials.gov identifiers: NCT02054897, NCT01930188, NCT01885208, NCT02128932, NCT02305381, NCT01720446, NCT02207374, NCT02254291, NCT02906930, NCT02863328, NCT02607865, NCT02863419, NCT02827708, NCT02692716, NCT02849080, NCT03021187, NCT03018028, NCT03015220.
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New trial: Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data (clinicaltrials.gov) - Sep 30, 2020
P, N=200000, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Byetta (exenatide) / AstraZeneca, semaglutide SC once-daily (NN9536) / Novo Nordisk
Retrospective data, Journal: GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. (Pubmed Central) - Sep 30, 2020
GLP-1RA also reduced the risk cardiovascular death by 12%, nonfatal stroke by 16%, hospitalisation for heart failure by 9%, all-cause mortality by 11%, and the broad composite kidney outcome by 17%; the latter appeared to be driven by a reduction in macroalbuminuria only (HR = 0.76, 0.68-0.86, P = 0.003). GLP-1RA have moderate benefits on MACE, and also reduce hospitalisation for heart failure and all-cause mortality; they also have robust benefits on reducing the incidence of macroalbuminuria, without affecting the progression of diabetic renal disease.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice (clinicaltrials.gov) - Sep 27, 2020
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
GLP-1RA have moderate benefits on MACE, and also reduce hospitalisation for heart failure and all-cause mortality; they also have robust benefits on reducing the incidence of macroalbuminuria, without affecting the progression of diabetic renal disease. Trial primary completion date: Sep 2020 --> Jul 2022
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
The new oral Semaglutide (GLP-1 agonist) as effective as injection #NoMoreNeedles #EASD2020... (Twitter) - Sep 23, 2020
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice (clinicaltrials.gov) - Sep 22, 2020
P, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data: Semaglutide, oral and injectable, greater weight losses in T2 #diabetes in a network meta analysis . #EASD2020 (Twitter) - Sep 22, 2020
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Oral semaglutide works regardless of baseline A1c, diabetes duration, baseline meds and ethnicity.#EASD2020 (Twitter) - Sep 21, 2020
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (clinicaltrials.gov) - Sep 19, 2020
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial primary completion date: Sep 2020 --> Jul 2022 Not yet recruiting --> Enrolling by invitation
- Rybelsus (semaglutide oral) / Novo Nordisk
[VIRTUAL] Oral Semaglutide Provides Less Value for Money Than Subcutaneous Semaglutide for the Prevention of Major Adverse Cardiovascular Events, but Significantly More Value for Money for the Prevention of Cardiovascular Mortality (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_3438;
Subcutaneous semaglutide prescribed for the prevention of MACE in patients with T2DM is moderately cost-saving compared to oral semaglutide for the same purpose. However, for the prevention of CVM, the oral version provides significantly better economic value.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_2952;
P3
In this post hoc analysis of SUSTAIN 6 and PIONEER 6, over half of patients had elevated TG levels (>151 mg/dL). Semaglutide consistently reduced the risk of MACE vs placebo across baseline TG levels.
- Rybelsus (semaglutide oral) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
[VIRTUAL] Empagliflozin Provides More Value for Money Than Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_1581;
The annualized NNT of empagliflozin and oral semaglutide prescribed for the prevention of CVM in patients with T2DM and established CVD is similar. Therefore, the lower cost of empagliflozin results in a lower CNT and better value for money.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times (clinicaltrials.gov) - Sep 9, 2020
P1, N=156, Recruiting, Sponsor: Novo Nordisk A/S
Therefore, the lower cost of empagliflozin results in a lower CNT and better value for money. Not yet recruiting --> Recruiting
- || semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical, Review, Journal: Incorporating and Interpreting Regulatory Guidance on Estimands in Diabetes Clinical Trials: The PIONEER 1 Randomized Clinical Trial as an Example. (Pubmed Central) - Sep 9, 2020
In PIONEER 1, two estimands were employed for each efficacy endpoint and labelled as: (1) the treatment policy estimand, which assesses the treatment effect regardless of the use of rescue medication or discontinuation of trial product, and provides a broad perspective of the treatment effect in the population of patients with type 2 diabetes in clinical practice; and (2) the trial product estimand, which assesses the treatment effect had all patients remained on trial product for the planned duration of the trial without rescue medication, and thereby provides information on the anticipated treatment effect of the medication. Both approaches are complementary in understanding the effect of the studied treatments.
- | Rybelsus (semaglutide oral) / Novo Nordisk, metformin / Generic mfg.
Journal: Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus. (Pubmed Central) - Sep 8, 2020
Relevance to Patient Care and Clinical Practice: Oral semaglutide may be appropriate as second- or third-line add-on therapy for patients with T2DM who are not meeting treatment goals on metformin and are overweight and reluctant to use an injectable drug. Oral semaglutide appears safe and effective as monotherapy and add-on pharmacological therapy for the treatment of T2DM.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice (clinicaltrials.gov) - Sep 7, 2020
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Oral semaglutide appears safe and effective as monotherapy and add-on pharmacological therapy for the treatment of T2DM. Not yet recruiting --> Enrolling by invitation
- || Clinical, PK/PD data, Journal: Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. (Pubmed Central) - Sep 5, 2020
Not yet recruiting --> Enrolling by invitation Oral semaglutide or SNAC alone did not appear to affect the exposure of lisinopril, warfarin, or digoxin, and, based on its wide therapeutic index, the higher metformin exposure with oral semaglutide was not considered clinically relevant.
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (clinicaltrials.gov) - Sep 2, 2020
P, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice (clinicaltrials.gov) - Sep 2, 2020
P, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People (clinicaltrials.gov) - Aug 23, 2020
P1, N=175, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, HEOR: Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide. (Pubmed Central) - Aug 23, 2020
We conclude that the additional costs incurred to produce extra semaglutide for the oral formulation are cost effective, given the greater quality of life experienced when taking a capsule over a weekly injection. We also demonstrate that the potency of semaglutide allows the formulation to be cost effective, and less potent drugs will require increased oral bioavailability to make a cost effective oral formulation.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, PK/PD data, Journal: Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. (Pubmed Central) - Aug 20, 2020
P1
The pharmacokinetic results supported that oral semaglutide is suitable for once-daily dosing. CLINICALTRIALS.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times (clinicaltrials.gov) - Aug 13, 2020
P1, N=156, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Rybelsus® — erstes verfügbares orales GLP-1-Analogon : Typ-2-Diabetes. (Pubmed Central) - Aug 12, 2020
CLINICALTRIALS. No abstract available
- || Rybelsus (semaglutide oral) / Novo Nordisk
.@novonordiskus adapts Rybelsus launch to the coronavirus era. https://t.co/a6PaGXYxTW (Twitter) - Jul 30, 2020
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal: A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. (Pubmed Central) - Jul 30, 2020
This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability.
- || Rybelsus (semaglutide oral) / Novo Nordisk, metformin / Generic mfg., Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical, Journal: Oral Semaglutide versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. (Pubmed Central) - Jul 29, 2020
At week 52, HbA and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
- || Rybelsus (semaglutide oral) / Novo Nordisk, metformin / Generic mfg.
Clinical, Journal: Efficacy, Safety and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin ± Metformin in Patients with Type 2 Diabetes: the PIONEER 8 Trial. (Pubmed Central) - Jul 29, 2020
P3
Oral semaglutide was superior to placebo in reducing HbA and body weight when added to insulin ± metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide-1 receptor agonists.
- | Rybelsus (semaglutide oral) / Novo Nordisk, metformin / Generic mfg., Lantus (insulin glargine) / Sanofi
Journal, HEOR: Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. (Pubmed Central) - Jul 24, 2020
The safety profile was consistent with other glucagon-like peptide-1 receptor agonists. Empagliflozin 25 mg is a cost-effective treatment option versus oral semaglutide 14 mg, when used in addition to metformin, for the treatment of T2DM patients in the UK.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, Journal: Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes. (Pubmed Central) - Jul 19, 2020
Empagliflozin 25 mg is a cost-effective treatment option versus oral semaglutide 14 mg, when used in addition to metformin, for the treatment of T2DM patients in the UK. No abstract available
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, P2/3 data, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal, Monotherapy: Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. (Pubmed Central) - Jul 19, 2020
P3
No abstract available This study showed that oral semaglutide provides significant reductions in HbA compared with placebo in a dose-dependent manner in Japanese patients with type 2 diabetes, and has a safety profile consistent with that of GLP-1 receptor agonists.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Clinical, P3 data, Clinical Trial,Phase III, Journal: Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. (Pubmed Central) - Jul 19, 2020
P3
Oral semaglutide was well tolerated in Japanese patients with type 2 diabetes. Once-daily oral semaglutide significantly reduced HbA (14 mg dose) and bodyweight (7 mg and 14 mg doses) versus weekly subcutaneous dulaglutide 0·75 mg by week 52.